# Kenneth A Getz

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 58 papers | 1,462 citations | 16 h-index | 38 g-index |
| 63 ext. papers | 1,732 ext. citations | 4.3 avg, IF | 4.61 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 58 | Central challenges facing the national clinical research enterprise. *JAMA - Journal of the American Medical Association*, **2003**, 289, 1278-87 | 26.8 | 857 |
| 57 | Assessing the impact of protocol design changes on clinical trial performance. *American Journal of Therapeutics*, **2008**, 15, 450-7 | 0.9 | 105 |
| 56 | Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. *Therapeutic Innovation and Regulatory Science*, **2018**, 52, 220-229 | 1.1 | 60 |
| 55 | Measuring the Incidence, Causes, and Repercussions of Protocol Amendments. *Drug Information Journal*, **2011**, 45, 265-275 | | 36 |
| 54 | Global Public Attitudes About Clinical Research and Patient Experiences With Clinical Trials. *JAMA Network Open*, **2018**, 1, e182969 | 10.1 | 33 |
| 53 | Racial disparities among clinical research investigators. *American Journal of Therapeutics*, **2008**, 15, 3-11 | 0.9 | 29 |
| 52 | Evaluating the completeness and accuracy of MedWatch data. *American Journal of Therapeutics*, **2014**, 21, 442-6 | 0.9 | 28 |
| 51 | Improving protocol design feasibility to drive drug development economics and performance. *International Journal of Environmental Research and Public Health*, **2014**, 11, 5069-80 | 4.5 | 26 |
| 50 | A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals. *Drug Safety*, **2016**, 39, 1117-1127 | 5 | 25 |
| 49 | The Impact of Protocol Amendments on Clinical Trial Performance and Cost. *Therapeutic Innovation and Regulatory Science*, **2016**, 50, 436-441 | 1.1 | 24 |
| 48 | Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. *JAMA - Journal of the American Medical Association*, **2021**, 326, 257-265 | 26.8 | 24 |
| 47 | Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics*, **2015**, 22, 117-24 | 0.9 | 19 |
| 46 | Variability in Protocol Design Complexity by Phase and Therapeutic Area. *Drug Information Journal*, **2011**, 45, 413-420 | | 21 |
| 45 | Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 103-116 | 1.1 | 17 |
| 44 | New Benchmarks Characterizing Growth in Protocol Design Complexity. *Therapeutic Innovation and Regulatory Science*, **2018**, 52, 22-28 | 1.1 | 17 |
| 43 | Meeting the obligation to communicate clinical trial results to study volunteers. *Expert Review of Clinical Pharmacology*, **2012**, 5, 149-56 | 3.7 | 16 |
| 42 | Establishing Return-on-Investment Expectations for Patient-Centric Initiatives. *Therapeutic Innovation and Regulatory Science*, **2015**, 49, 745-749 | 1.1 | 14 |

| | | | |
|---|---|---|---|
| 41 | Examining and Enabling the Role of Health Care Providers as Patient Engagement Facilitators in Clinical Trials. *Clinical Therapeutics*, **2017**, 39, 2203-2213 | 3.4 | 14 |
| 40 | Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. *Clinical Infectious Diseases*, **2018**, 66, 72-80 | 11.3 | 11 |
| 39 | The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times. *Therapeutic Innovation and Regulatory Science*, **2014**, 48, 482-487 | 1.1 | 11 |
| 38 | Reflections on the Evolution of Patient Engagement in Drug Development. *Pharmaceutical Medicine*, **2019**, 33, 179-185 | 2.2 | 10 |
| 37 | Evaluating the Completeness of ClinicalTrials.gov. *Therapeutic Innovation and Regulatory Science*, **2019**, 53, 307-317 | 1.1 | 9 |
| 36 | New Governance Mechanisms to Optimize Protocol Design. *Therapeutic Innovation and Regulatory Science*, **2013**, 47, 651-655 | 1.1 | 9 |
| 35 | Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. *Therapeutic Innovation and Regulatory Science*, **2019**, 216847901881751 | 1.1 | 8 |
| 34 | Taking the pulse of strategic outsourcing relationships. *Clinical Therapeutics*, **2014**, 36, 1349-55 | 3.4 | 8 |
| 33 | Assessing Patient Participation Burden Based on Protocol Design Characteristics. *Therapeutic Innovation and Regulatory Science*, **2019**, 2168479019867284 | 1.1 | 5 |
| 32 | Generational Value Differences Affecting Public Perceptions of and Willingness to Participate in Clinical Trials. *Therapeutic Innovation and Regulatory Science*, **2015**, 49, 940-946 | 1.1 | 5 |
| 31 | Baseline Assessment of a Global Clinical Investigator Landscape Poised for Structural Change. *Therapeutic Innovation and Regulatory Science*, **2017**, 51, 575-581 | 1.1 | 4 |
| 30 | Therapeutic area variability in the collection of data supporting protocol end points and objectives. *Clinical Investigation*, **2014**, 4, 125-130 | | 3 |
| 29 | Factors Influencing Investigative Site Willingness and Ability to Participate in Clinical Trials. *Drug Information Journal*, **2011**, 45, 377-390 | | 3 |
| 28 | Quantifying Patient Subpopulation Disparities in New Drugs and Biologics Approved Between 2007 and 2017. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 1541-1550 | 1.1 | 3 |
| 27 | The Expanding Outside Clinical Services Contractor Marketplace. *Clinical Research and Regulatory Affairs*, **1997**, 14, 191-204 | | 3 |
| 26 | Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices. *Drug Safety*, **2015**, 38, 687-92 | 5 | 2 |
| 25 | Are Pharmacists a Viable Channel for Education about Clinical Trial Participation?. *Drug Information Journal*, **2011**, 45, 443-453 | | 2 |
| 24 | Impact of In-Pharmacy Education on PatientsTKnowledge and Attitudes About Clinical Trials. *Therapeutic Innovation and Regulatory Science*, **2013**, 47, 336-340 | 1.1 | 2 |

| | | | |
|---|---|---|---|
| 23 | Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. *Clinical Therapeutics*, **2020**, 42, e150-e159 | 3.4 | 2 |
| 22 | Establishing Consensus Understanding of the Barriers to Drug Development in Lupus. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 1159-1165 | 1.1 | 2 |
| 21 | Analysis of Review Times for Recent 505(b)(2) Applications. *Therapeutic Innovation and Regulatory Science*, **2017**, 51, 651-656 | 1.1 | 2 |
| 20 | Benchmarking Patient Recruitment and Retention Practices. *Therapeutic Innovation and Regulatory Science*, **2021**, 55, 19-32 | 1.1 | 2 |
| 19 | Trends driving clinical trials into large clinical care settings. *Nature Reviews Drug Discovery*, **2018**, 17, 703-704 | 62 | 2 |
| 18 | Public and patient usage and expectations for clinical trial registries **2006**, 47-58 | | 2 |
| 17 | The Impact of Bad Protocols **2015**, 105-116 | | 1 |
| 16 | Unfulfilled translation opportunities in industry sponsored clinical trials. *Contemporary Clinical Trials*, **2013**, 35, 80-6 | 2.2 | 1 |
| 15 | Communicating trial results to study volunteers: what does the future hold?. *Clinical Investigation*, **2014**, 4, 777-779 | | 1 |
| 14 | Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical Trials. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 1330-1338 | 1.1 | 1 |
| 13 | US Physician and Nurse Proclivity to Refer Their Patients Into Clinical Trials. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 404-410 | 1.1 | 1 |
| 12 | Assessing Patient Participation Burden Based on Protocol Design Characteristics. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 598-604 | 1.1 | 1 |
| 11 | The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. *Lupus Science and Medicine*, **2021**, 8, | 4.5 | 1 |
| 10 | Evaluating the Feasibility and Validity of a New Tool to Assess Organizational Preparedness and Capabilities to Support Patient Engagement in Drug Development. *Therapeutic Innovation and Regulatory Science*, **2021**, 55, 1193-1198 | 1.1 | 0 |
| 9 | Protocol Design Variables Highly Correlated with, and Predictive of, Clinical Trial Performance.. *Therapeutic Innovation and Regulatory Science*, **2022**, 56, 333 | 1.1 | 0 |
| 8 | Differences in Clinical Research Perceptions and Experiences by Age Subgroup. *Therapeutic Innovation and Regulatory Science*, **2019**, 216847901881472 | 1.1 | |
| 7 | US Physician and Nurse Proclivity to Refer Their Patients Into Clinical Trials. *Therapeutic Innovation and Regulatory Science*, **2019**, 216847901983796 | 1.1 | |
| 6 | Bridging the Academia/Industry Chasm: Proposed Solutions. *Journal of Clinical Pharmacology*, **2016**, 56, 1457-1460 | 2.8 | |

# List of Publications

| | | |
|---|---|---|
| 5 | Site Characteristics Influencing the Translation of Clinical Research Into Clinical Practice. *Therapeutic Innovation and Regulatory Science*, **2014**, 48, 628-634 | 1.1 |
| 4 | The Promise and Progress of DIA 2011. *Drug Information Journal*, **2011**, 45, 119-120 | |
| 3 | Benchmarking the Vendor Qualification Process. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 1349-1358 | 1.1 |
| 2 | Tufts Center for the Study of Drug Development Employs Broadly Engaged Team Science to Explore the Challenges of Pharmaceutical Research and Development **2022**, 55-63 | |
| 1 | Benchmarking Protocol Deviations and Their Variation by Major Disease Categories.. *Therapeutic Innovation and Regulatory Science*, **2022**, 1 | 1.1 |